Evidence map›Paper›PMID 19894024›Full record

ArticleInflammopharmacology2010

Genistein, a potent inhibitor of secretory phospholipase A2: a new insight in down regulation of inflammation.

Kattepura K Dharmappa, Riyaz Mohamed, Holenarasipura V Shivaprasad, Bannikuppe Sannanaik Vishwanath

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Eburicoic Acid fromJournal of inflammation research · 2026
    Article
  4. Review
  5. Review
  6. Review on Natural Agents as Aromatase Inhibitors: Management of Breast Cancer.Combinatorial chemistry & high throughput screening · 2024
    Review
  7. Review
  8. Article
  9. Sinapicacid Inhibits Group IIA Secretory Phospholipase AAntioxidants (Basel, Switzerland) · 2022
    Article
  10. Group IIA secreted phospholipase AScientific reports · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Natural Products for the Management and Prevention of Breast Cancer.Evidence-based complementary and alternative medicine : eCAM · 2018
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kattepura K DharmappaDepartment of Studies in Biochemistry, University of Mysore, Manasagangotri, Mysore 570006, India.
Riyaz Mohamed
Holenarasipura V Shivaprasad
Bannikuppe Sannanaik Vishwanath
University of Mysore · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSome of the legumes, spices and medicinal herbs rich in genistein are known for their anti-inflammatory properties. Anti-inflammatory property of these herbs is determined by subjecting secretory phospholipase A(2) (sPLA(2)) inhibition, a key enzyme in the inflammatory reactions by genistein. MATERIALS AND

methodsGenistein was assessed for inhibition of sPLA(2) activity using (14)C-oleate radiolabelled Escherichia coli membrane as substrate. The enzyme-inhibitor interaction was established by intrinsic fluorescence and circular dichroism studies. The in vivo anti-inflammatory activity was tested by injecting sPLA(2), Vipera russelli venom phospholipase-V (VRV-PL-V) with different concentrations of genistein in the range of 3-21 muM into intra plantar surface of right hind footpad of mice. Systemic effect was tested by administering the genistein (21 muM) i.p. 30 min before and immediately after sPLA(2) injection.

resultGenistein inhibited sPLA(2) enzymes of inflammatory exudates (human synovial fluid and human pleural fluid) and snake venoms (VRV-PL-V and Naja naja phospholipase-I) in a concentration dependent manner with IC(50) values ranging from 5.75 to 11.75 muM. Increasing the calcium (Ca(2+)) concentration from 2.5 to 15 mM and substrate concentration up to 120 nM did not alter the level of inhibition. Genistein alters the intrinsic fluorescence intensity and shown apparent shift in far ultra violet-circular dichroism spectra of VRV-PL-V, indicating the direct interaction with enzyme. Genistein also inhibited the VRV-PL-V induced mouse paw oedema in a concentration dependent manner. The genistein at 21 muM concentration administered immediately after the VRV-PL-V injection, effectively neutralized the oedema inducing activity.

conclusionGenistein inhibited sPLA(2) activity of both inflammatory exudates and snake venoms in a concentration dependent manner and sPLA(2) induced mouse paw oedema. The study partially explains the observed anti-inflammatory property of several medicinal herbs which containing genistein.

Indexed as

AnimalsDose-Response Relationship, DrugDown-RegulationGenisteinHumansInflammationInflammation MediatorsMicePhospholipases A2, SecretoryProtein Kinase InhibitorsSnake VenomsGenisteinInflammation MediatorsPhospholipases A2, SecretoryProtein Kinase InhibitorsSnake Venoms

Identifiers

PMID19894024
OpenAlexW2092691796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.